MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor

Chen,Shi; Wang,Qian; Zhou,Xian‑Mei; Zhu,Ji‑Ping; Li,Tian; Huang,Mao

doi:10.3892/mmr.2016.5332

MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor

Authors:
- Shi Chen
- Qian Wang
- Xian‑Mei Zhou
- Ji‑Ping Zhu
- Tian Li
- Mao Huang
View Affiliations

Affiliations: Department of Respiratory Disease, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Respiratory Medicine, Affiliated Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R. China
Published online on: May 24, 2016 https://doi.org/10.3892/mmr.2016.5332
Pages: 949-954

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑27b has been reported to participate in regulating the activity of non‑small cell lung carcinoma (NSCLC) cells. Additionally, when downregulated in NSCLC it promotes resistance to docetaxel; however, the underlying molecular mechanism remains largely unknown. Using reverse transcription‑quantitative polymerase chain reaction, the present study determined that the expression of miR‑27b was significantly reduced in NSCLC cells that were resistant to docetaxel. In addition, epidermal growth factor receptor (EGFR) was identified as a possible target of miR‑27b by searching the online miRNA database, TargetScan. A luciferase assay further validated EGFR as an effective target gene of miR‑27b. In addition, it was determined that in tumor tissue samples resistant to docetaxel miR‑27b was significantly downregulated, whilst EGFR was significantly upregulated. miR‑27b negatively regulated the expression of EGFR. This was evident as the transfection of miR‑27b mimics led to downregulation of the expression levels of EGFR, whilst miR‑27b inhibitors upregulated the expression levels of EGFR. Furthermore, it was demonstrated that the transfection of miR‑27b mimics significantly suppressed the apoptosis and promote the viability of A549 human lung carcinoma cells. In line with this, the introduction of miR‑27b inhibitors significantly induced apoptosis and inhibited the proliferation of A549 cells. These results indicate that miR‑27b may promote NSCLC cell viability and enhance resistance to docetaxel treatment through direct inhibition of EGFR expression. Additionally, miR‑27b may become a promising molecular target for improving the effectiveness of chemotherapy with docetaxel.

View Figures

View References

1	Jalal SI, Ademuyiwa FO and Hanna NH: The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol. 21:110–115. 2009. View Article : Google Scholar : PubMed/NCBI
2	Edelman MJ and Gandara DR: Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 37:385–393. 1996. View Article : Google Scholar : PubMed/NCBI
3	Peng Y, Yu S, Li H, Xiang H, Peng J and Jiang S: MicroRNAs: Emerging roles in adipogenesis and obesity. Cell Signal. 26:1888–1896. 2014. View Article : Google Scholar : PubMed/NCBI
4	Palumbo S, Miracco C, Pirtoli L and Comincini S: Emerging roles of microRNA in modulating cell-death processes in malignant glioma. J Cell Physiol. 229:277–286. 2014. View Article : Google Scholar
5	Liu R, Liu X, Zheng Y, Gu J, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Ge D and Chu Y: MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett. 8:2193–2200. 2014.PubMed/NCBI
6	Ning FL, Wang F, Li ML, Yu ZS, Hao YZ and Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol. 9:1432014. View Article : Google Scholar : PubMed/NCBI
7	Zhang F, Li Y, Wu H, Qi K, You J, Li X, Zu L, Pan Z, Wang Y, Li Y, et al: MiR-192 confers cisplatin resistance by targeting Bim in lung cancer. Zhongguo fei ai za zhi. 17:384–390. 2014.In Chinese. PubMed/NCBI
8	Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, Huang H, Li S and Zhao J: MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFβR2 in NSCLC. PLoS One. 9:e946392014. View Article : Google Scholar
9	Rui W, Bing F, Hai-Zhu S, Wei D and Long-Bang C: Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med. 14:206–214. 2010. View Article : Google Scholar
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
11	Walker S: Updates in non-small cell lung cancer. Clin J Oncol Nurs. 12:587–96. 2008. View Article : Google Scholar : PubMed/NCBI
12	Gkiozos I, Charpidou A and Syrigos K: Developments in the treatment of non-small cell lung cancer. Anticancer Res. 27:2823–2827. 2007.PubMed/NCBI
13	Bernstein ED, Herbert SM and Hanna NH: Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. Ann Surg Oncol. 13:291–301. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pirker R: Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res. 3:305–310. 2014.
15	Bi N and Wang L: Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: Challenges in the selection of appropriate chemotherapy. Semin Radiat Oncol. 25:122–132. 2015. View Article : Google Scholar : PubMed/NCBI
16	Matikas A, Mistriotis D, Georgoulias V and Kotsakis A: Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin Lung Cancer. 16:252–261. 2015. View Article : Google Scholar : PubMed/NCBI
17	Pilkington G, Boland A, Brown T, Oyee J, Bagust A and Dickson R: A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. Feb 6–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
18	Paul I and Jones JM: Apoptosis block as a barrier to effective therapy in non small cell lung cancer. World J Clin Oncol. 5:588–594. 2014. View Article : Google Scholar : PubMed/NCBI
19	Horwitz SB: Taxol (paclitaxel): Mechanisms of action. Ann Oncol. 5(Suppl 6): S3–S6. 1994.PubMed/NCBI
20	Geney R, Ungureanu M, Li D and Ojima I: Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med. 40:918–925. 2002. View Article : Google Scholar : PubMed/NCBI
21	McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 1785:96–132. 2007.PubMed/NCBI
22	Tay FC, Lim JK, Zhu H, Hin LC and Wang S: Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev. 81:117–127. 2015. View Article : Google Scholar
23	Wan L, Zhang L, Fan K and Wang J: MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One. 8:e606872013. View Article : Google Scholar : PubMed/NCBI
25	Ishteiwy RA, Ward TM, Dykxhoorn DM and Burnstein KL: The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One. 7:e521062012. View Article : Google Scholar
26	Lee JJ, Drakaki A, Iliopoulos D and Struhl K: MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 31:3818–3825. 2012. View Article : Google Scholar
27	Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
28	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
29	Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, Guo J and Ge D: Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 81:259–265. 2013. View Article : Google Scholar : PubMed/NCBI
30	Edelman MJ: Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer. 10:S30–S34. 2009. View Article : Google Scholar : PubMed/NCBI
31	Morales-Cano D, Calviño E, Rubio V, Herráez A, Sancho P, Tejedor MC and Diez JC: Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition. Exp Toxicol Pathol. 65:1101–1108. 2013. View Article : Google Scholar : PubMed/NCBI
32	Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010. View Article : Google Scholar : PubMed/NCBI
33	Wan YF, Guo XQ, Wang ZH, Ying K and Yao MH: Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 25:378–384. 2004.PubMed/NCBI
34	Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, Koga K, Mibu R, Nakamura M and Katano M: Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res. 29:261–270. 2009.PubMed/NCBI